Sponsor
Cambridge, MA —Arteaus is a product-focused biotechnology company developing a novel treatment for migraine prevention. Arteaus is developing an antibody to calcitonin gene-related peptide (CGRP) as a novel approach for the prevention of migraine headaches. The world-wide rights to develop the antibody have been licensed from Eli Lilly and Company in an innovative collaboration that leverages Lilly’s capabilities and experience developing the antibody with Arteaus’ virtual and capital-efficient approach to achieving clinical proof of concept.
